David Cuthbert, MD, FRCPC, Fellow,
Department of Radiation Oncology, Princess Margaret Hospital
and University of Toronto.
Padraig Warde, MB, MRCPI, FRCPC, Professor, Department of
Radiation Oncology, Princess Margaret Hospital and University
of Toronto; Deputy Head, Radiation Medicine Program, Princess
Margaret Hospital, Toronto.
To view the complete article click
here (pdf format)
TRIAL SUMMARY: Quality of life benefits linked with
intermittent androgen suppression
Canadian Association Of Radiation Oncology
(CARO) September 7-11, 2011, Winnipeg, Manitoba.
Androgen deprivation therapy is effective
in patients with prostate cancer who relapse after primary treatment.
Until now, the standard strategy has been
continuous treatment until death.
What this study showed
An intermittent approach to androgen deprivation
therapy is safe and results in improved quality of life for patients
when they are off treatment.
Further research is needed to determine
which patients will benefit from this approach, when androgen
deprivation therapy should be started in these patients, and the
impact of new agents such as abiraterone and MDV1000.